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Introduction
============

Sickle cell disease (SCD) is one of the most important autosomal recessive diseases. In the Kingdom of Saudi Arabia (KSA), the prevalence of the sickle cell trait ranges from 2% to 27%, and as many as 2.6% of affected individuals develop SCD. SCD is characterized by vaso-occlusive events, hemolytic crises, and organ damage \[[@REF1]\].

Renal impairment is a chronic complication of SCD and a major factor associated with mortality \[[@REF2]\]. This association with mortality is stronger than that observed with an episode of acute stroke, a febrile episode with positive blood culture, acute chest syndrome, or severe acute anemia \[[@REF3]\].

In SCD, microalbuminuria is one of the most common clinical manifestations of sickle cell nephropathy (SCN) \[[@REF4]-[@REF5]\], which appears to be associated with a more rapid deterioration in renal function \[[@REF6]\]. The reported incidence of microalbuminuria in children with SCD ranges from 18.4% to 46% \[[@REF7]-[@REF9]\]. The identification of microalbuminuria in a patient with SCD is a predictor of end-organ disease, including renal damage \[[@REF10]-[@REF11]\]. Children with SCD experience hyperfiltration and hyperperfusion, which are associated with renal damage \[[@REF12]-[@REF13]\]. Therefore, the early detection of microalbuminuria may represent an important early sign of renal disease \[[@REF14]\].

A prolonged period of microalbuminuria precedes persistent proteinuria, which is followed by renal failure in SCD patients \[[@REF15]\]. Therefore, the identification of risk factors for microalbuminuria may allow earlier intervention to prevent renal complications \[[@REF7]\]. The KSA faces a high burden of SCD, with a prevalence rate of 2.6% in newborns in a population of \>24 million, and children with SCD are prone to developing microalbuminuria and chronic renal failure with advancing age. Nevertheless, previous research in the KSA has not addressed this problem. Therefore, this study aimed to determine the prevalence of microalbuminuria in children with SCD and to identify the risk factors associated with microalbuminuria in children with SCD at King Abdulaziz University Hospital (KAUH).

Materials and methods
=====================

The study was approved by the institutional review board of the KAUH (reference number: 186-19). This cross-sectional prevalence study retrospectively reviewed medical records of children aged 2-18 years who were diagnosed with SCD and visited the KAUH Pediatric Sickle Cell Clinic.

The following data were obtained from recent outpatient follow-up visits: sex, age, nationality, weight, height, ABO blood group type, sickle cell genotype, blood transfusion (BT) status, and number of transfusions. Additionally, the frequencies of vaso-occlusive events and SCD complications were collected.

From the urinalysis results, microalbuminuria was defined as a protein level of \>1+. Hematuria was defined as a RBC count \>5.

Statistical analysis

Descriptive statistics was used to assess the study participants' demographic characteristics. Means ± standard deviations (SDs) and median values were used to describe continuous variables. Frequencies with proportions are used to report categorical variables. Numerical variables were compared between groups using the independent t-test, whereas categorical variables were compared using the chi-square and Fisher's exact tests. Statistical significance was set at a P value \<0.05. All statistical analyses were performed using IBM SPSS statistics, version 23 (IBM, Armonk, NY, USA).

Results
=======

The prevalence of microalbuminuria and its associated factors were assessed in 322 pediatric patients with SCD. The patients\' characteristics are presented in Table [1](#TAB1){ref-type="table"}.

###### Descriptive statistics of all patients enrolled in the study (N=322).

SD, standard deviation

  --------------------------------------------- ------- ------------ --------
  Variable                                      n       Percentage   
  Nationality                                                        
  Non-Saudi Arabian                             185     57.5         
  Saudi Arabian                                 137     42.5         
  Gender                                                             
  Female                                        157     48.8         
  Male                                          165     51.2         
  Age group                                                          
  2 to 5 years                                  30      9.3          
  6 to 10 years                                 87      27.0         
  11 to 14 years                                77      23.9         
  15 to 18 years                                128     39.8         
  Sickle cell genotype                                               
  Hemoglobin SB 0 (Beta-zero) thalassemia       4       1.2          
  Hemoglobin SB+ (beta) thalassemia             41      12.7         
  Hemoglobin SS disease (sickle cell disease)   233     72.4         
  Sickle cell trait (hemoglobin S disease)      44      13.7         
  Microalbuminuria                                                   
  No                                            291     90.4         
  Yes                                           31      9.6          
  Hematuria                                                          
  No                                            296     91.9         
  Yes                                           26      8.1          
  Blood type                                                         
  A RhD negative (A-)                           3       0.9          
  A RhD positive (A+)                           84      26.1         
  AB RhD positive (AB+)                         15      4.7          
  B RhD negative (B-)                           3       0.9          
  B RhD positive (B+)                           32      9.9          
  O RhD negative (O-)                           9       2.8          
  O RhD positive (O+)                           176     54.7         
  Blood transfusions                                                 
  No                                            143     44.4         
  Yes                                           179     55.6         
  Frequency of:                                                      
  Pneumonia                                     30      9.3          
  Priapism                                      3       0.9          
  Avascular necrosis                            3       0.9          
  Acute chest syndrome                          31      9.6          
  Aplasia                                       2       0.6          
  Stroke                                        14      4.3          
  Acute coronary syndrome                       10      3.1          
  Dactylitis                                    3       0.9          
  Spleen sequestration                          24      7.5          
  Gallbladder stones                            11      3.4          
  Osteomyelitis                                 23      7.1          
                                                Mean    SD           Median
  Age (years)                                   12.43   4.64         13.00
  Number of blood transfusions                  8.67    26.71        1.00
  --------------------------------------------- ------- ------------ --------

The characteristics of the nonmicroalbuminuria (291 patients) and microalbuminuria group (31 patients) and comparisons of different variables between the groups are shown in Table [2](#TAB2){ref-type="table"}. The prevalence of hematuria differed significantly between the groups, and was higher in the microalbuminuria group than in the nonmicroalbuminuria group (P = 0.007). However, a significant difference was observed in the distribution of blood groups (P = 0.022). The percentage of acute chest syndrome was significantly higher in the microalbuminuria group than in the nonmicroalbuminuria group (P = 0.005). The percentage of gallbladder stones was significantly higher in the microalbuminuria group than in the nonmicroalbuminuria group (P = 0.014). The mean number of BTs was higher in the nonmicroalbuminuria group than in the microalbuminuria group (P = 0.002). No other variables differed significantly between the groups.

###### Comparison of different variables between nonmicroalbuminuria and microalbuminuria patients.

SD, standard deviation; \*, significant P-value

  --------------------------------------------- ---------------------------------- ------------------------------ --------- ------- --------- ------- ---------
                                                Without microalbuminuria (n=291)   With microalbuminuria (n=31)   P-value                             
  n                                             \%                                 n                              \%                                  
  Nationality                                                                                                                                         
  Non-Saudi Arabian                             167                                57.4                           18        58.1    0.942             
  Saudi Arabian                                 124                                42.6                           13        41.9                      
  Sex                                                                                                                                                 
  Female                                        144                                49.5                           13        41.9    0.424             
  Male                                          147                                50.5                           18        58.1                      
  Age group                                                                                                                                           
  2 to 5 years                                  27                                 9.3                            3         9.7     0.432             
  6 to 10 years                                 82                                 28.2                           5         16.1                      
  11 to 14 years                                70                                 24.1                           7         22.6                      
  15 to 18 years                                112                                38.5                           16        51.6                      
  Sickle cell genotype                                                                                                                                
  Hemoglobin SB 0 (beta-zero) thalassemia       4                                  1.4                            0         0.0     0.928             
  Hemoglobin SB+ (beta) thalassemia             37                                 12.7                           4         12.9                      
  Hemoglobin SS disease (sickle cell disease)   210                                72.2                           23        74.2                      
  Sickle cell trait (Hemoglobin S disease)      40                                 13.7                           4         12.9                      
  Hematuria                                                                                                                                           
  No                                            272                                93.5                           24        77.4    0.007\*           
  Yes                                           19                                 6.5                            7         22.6                      
  Blood type                                                                                                                                          
  A RhD negative (A-)                           2                                  0.7                            1         3.2     0.022\*           
  A RhD positive (A+)                           75                                 25.8                           9         29.0                      
  AB RhD positive (AB+)                         10                                 3.4                            5         16.1                      
  B RhD negative (B-)                           3                                  1.0                            0         0.0                       
  B RhD positive (B+)                           31                                 10.7                           1         3.2                       
  O RhD negative (O-)                           9                                  3.1                            0         0.0                       
  O RhD positive (O+)                           161                                55.3                           15        48.4                      
  Blood transfusions                                                                                                                                  
  No                                            131                                45.0                           12        38.7    0.502             
  Yes                                           160                                55.0                           19        61.3                      
   Frequency of:                                                                                                                                      
  Pneumonia                                     28                                 9.6                            2         6.5     0.752             
  Priapism                                      3                                  1.0                            0         0.0     1                 
  Avascular necrosis                            3                                  1.0                            0         0.0     1                 
  Acute chest syndrome                          23                                 7.9                            8         25.8    0.005\*           
  Aplasia                                       2                                  0.7                            0         0.0     1                 
  Stroke                                        14                                 4.8                            0         0.0     0.377             
  Acute coronary syndrome                       10                                 3.4                            0         0.0     0.607             
  Dactylitis                                    3                                  1.0                            0         0.0     1                 
  Spleen sequestration                          22                                 7.6                            2         6.5     1                 
  Gallbladder stones                            7                                  2.4                            4         12.9    0.014\*           
  Osteomyelitis                                 20                                 6.9                            3         9.7     0.474             
                                                Without microalbuminuria           With microalbuminuria          P-value                             
  Mean                                          SD                                 Median                         Mean      SD      Median            
  Age                                           12.29                              4.62                           12.00     13.74   4.68      15.00   0.098
  Number of transfusions                        9.26                               27.97                          1.00      3.13    5.60      1.00    0.002\*
  --------------------------------------------- ---------------------------------- ------------------------------ --------- ------- --------- ------- ---------

Discussion
==========

Secondary renal failure affects 5%-20% of adult patients with SCD, and the progression of renal disorder begins in childhood \[[@REF16]\]. Microalbuminuria is one of the earliest manifestations of SCN. Hence, many studies have aimed to determine the prevalence of microalbuminuria among SCD patients as an indicator of the severity of the condition \[[@REF17]-[@REF18]\]. In this study, we determined the prevalence of microalbuminuria of 9.6% among pediatric patients with a mean age of 12.4 years. This condition emerged at a very young age (2 years) and increased continuously to the highest percentage among young adults (15-18 years), who exhibited a prevalence of 51.6%. The mean age and average prevalence of microalbuminuria among older patients in our study were consistent with the prevalence rates of 46% as reported by Dharnidharka et al. \[[@REF17]\] and of 39%-43% in adults with SCD as reported by McBurney et al. \[[@REF7]\]. However, the overall prevalence of microalbuminuria among all patients (9.6%) was lower than the average prevalence reported by those previous studies. Alkhunaizi et al. \[[@REF19]\] determined that the prevalence of microalbuminuria among adult Saudi Arabian patients (\>18 years) was 25%, very similar to our findings in the same age group.

Dharnidharka et al. \[[@REF17]\] and McBurney et al. \[[@REF7]\] reported that no microalbuminuria was detected in children aged \<7 years. Conversely, 9.7% of microalbuminuria patients in our study were aged 2-5 years. Our findings were supported by those of Aloni et al. \[[@REF20]\] who confirmed the presence of microalbuminuria in patients aged \<7 years. This early deterioration of glomerular function could be explained by the presence of certain factors, including a genetic predisposition, fetal hemoglobin (HbF) level, environmental factors, efficacy of medical care, and lifestyle factors associated with developing countries \[[@REF21]\]. However, the small sample size in our study may also reasonably explain these contradictory results. The studies by Dharnidharka et al. \[[@REF17]\] and by McBurney et al. \[[@REF7]\] enrolled 104 and 151 patients, respectively. Interestingly, when we compared the microalbuminuria and nonmicroalbuminuria groups, we observed no significant difference in terms of age (P = 0.432), suggesting that this was not a defining variable in either group. Nevertheless, age was a defining variable in the progression of microalbuminuria in the affected group.

Previous publications have reported a female predominance of microalbuminuria. Eke et al. reported a microalbuminuria prevalence of 9.7% among female patients and 6.1% among male patients \[[@REF5]\], while Okpere et al. \[[@REF22]\] reported results consistent with female predominance (45.3% vs. 20.4% of males). We did not observe a significant difference in sex between the microalbuminuria and nonmicroalbuminuria groups in our study, consistent with the findings of McBurney et al. \[[@REF7]\] and Dharnidharka et al. \[[@REF17]\]. Consequently, additional research evidence is needed to clarify these contrasting results.

Our findings demonstrated that microalbuminuria occurs in association with most hemoglobin genotypes. The highest percentage was observed with the Hb-ss genotype (74.2%) in the microalbuminuria group, similar to the results of a previous study conducted by Wigfall et al. \[[@REF23]\]. No microalbuminuria was detected in the HB-Sβ0 (Beta-Zero) thalassemia sub-group. Most previous studies included few patients with Sβ-thalassemia, and only a few studies have published mixed results regarding this patient group. Becton et al. \[[@REF18]\] reported that only one patient with Sβ-thalassemia had microalbuminuria.

We further examined the frequencies of several clinical complications that may be associated with microalbuminuria (Table [2](#TAB2){ref-type="table"}). We compared the microalbuminuria and nonmicroalbuminuria groups to identify definitive variables that varied significantly between the groups. Interestingly, we found that most patients in the microalbuminuria group experienced acute chest syndrome, gallbladder stones, osteomyelitis, pneumonia, and spleen sequestration, whereas none reported priapism, avascular necrosis, aplasia, stroke, acute coronary syndrome (ACS), or dactylitis. These findings were consistent with those reported by Dharnidharka et al. \[[@REF17]\] and McBurney et al. \[[@REF7]\] who observed no significant correlation between microalbuminuria and stroke and those of McBurney et al. \[[@REF7]\] and Becton et al. \[[@REF18]\] who reported no significant correlation with ACS. Our observation of a significant association between acute chest syndrome and microalbuminuria (P = 0.005) was consistent with the findings reported by Alvarez et al \[[@REF24]\]. By contrast, Bodas et al. \[[@REF25]\] reported that the glomerular filtration rate was not correlated with episodes of either stroke or acute chest syndrome, suggesting that the etiologies of these complications may differ from the etiologies underlying the development of SCN. However, that study included only 48 patients, and the relatively small sample size likely influenced the significant correlation between the two conditions.

We further identified a significant correlation between microalbuminuria and the development of gallbladder stones (P = 0.014). Our findings were consistent with those of Alexander-Reindorf et al. \[[@REF26]\] and Bond et al. \[[@REF27]\] who reported significantly higher morbidity and more hospital admissions among SCD patients with gallbladder stones. Additionally, the mean age in our microalbuminuria group was 13.74 years, consistent with the findings of Martins et al. \[[@REF28]\] who reported patients of ages 11 and 29 years, with a higher prevalence of cholelithiasis and gallbladder stones respectively.

In our study, the number of BTs was significantly and negatively associated with microalbuminuria, suggesting that BTs are a renoprotective process in the management of SCD. Alvarez et al. \[[@REF24]\] reported similar results and suggested that the early initiation of transfusion could protect the kidney and hinder deterioration of the SCN. However, the side effects of transfusion, such as iron overload, must be considered before starting this process. By contrast, Aloni et al. \[[@REF20]\] reported that BT is not a significant factor with respect to microalbuminuria.

Becton et al. \[[@REF18]\] stated that 36% of SCD patients presented with hematuria. However, the authors reported no significant difference in the frequency of hematuria between the microalbuminuria and nonmicroalbuminuria groups. By contrast, we observed a statistically significant difference in the frequency of hematuria between patients with and without microalbuminuria (P = 0.007). Our results were consistent with the findings of Sesso et al. \[[@REF29]\] who reported higher frequencies of hematuria in the Hb-SS and Hb-AS groups. The authors stated that hematuria is caused by the increased sickling of RBCs in the renal medulla, resulting in extravasation and ischemia. We further determined that most patients with SCD had type O RhD+ blood and that this variable varied significantly between the two groups (P = 0.022). This result was consistent with the findings of Alagwu et al. \[[@REF30]\] who reported an O blood group frequency of 63% among Hb-ss patients. This finding could be explained by the fact that the O Rh+ blood group is the most prevalent group in humans.

Conclusions
===========

In conclusion, our findings highlight the importance of early investigations (e.g., urinalysis) for the assessment of microalbuminuria and hematuria, as well as the determination of the degree of SCN. The observation that the average number of BTs was significantly higher in the nonmicroalbuminuria group than in the microalbuminuria group could suggest a protective role of transfusion against the development of microalbuminuria. Nevertheless, further investigations are needed to confirm our results. We also reported significantly higher rates of acute chest syndrome and gallbladder stones in patients with microalbuminuria. These factors must be considered, and special care should be provided to affected patients. We recommend routine screening of SCD patients for microalbuminuria and hematuria.
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